The TEAM Studies: A Review
1996; Wiley; Volume: 9; Issue: 5 Linguagem: Inglês
10.1111/j.1540-8183.1996.tb00643.x
ISSN1540-8183
AutoresJeffrey L. Anderson, Sanjeev Trehan,
Tópico(s)Cardiac Arrest and Resuscitation
ResumoJournal of Interventional CardiologyVolume 9, Issue 5 p. 361-372 The TEAM Studies: A Review JEFFREY L. ANDERSON M.D., FACC, Corresponding Author JEFFREY L. ANDERSON M.D., FACC From the Division of Cardiology, University of Utah, Salt Lake City, UtahAddress for reprints: Jeffrey L. Anderson, M.D., FACC, Chief, Division of Cardiology, LDS Hospital, 8th Ave. and C St., Salt Lake City, UT 84123. Fax: (801) 321–5087.Search for more papers by this authorSANJEEV TREHAN M.D., SANJEEV TREHAN M.D. From the Division of Cardiology, University of Utah, Salt Lake City, UtahSearch for more papers by this author JEFFREY L. ANDERSON M.D., FACC, Corresponding Author JEFFREY L. ANDERSON M.D., FACC From the Division of Cardiology, University of Utah, Salt Lake City, UtahAddress for reprints: Jeffrey L. Anderson, M.D., FACC, Chief, Division of Cardiology, LDS Hospital, 8th Ave. and C St., Salt Lake City, UT 84123. Fax: (801) 321–5087.Search for more papers by this authorSANJEEV TREHAN M.D., SANJEEV TREHAN M.D. From the Division of Cardiology, University of Utah, Salt Lake City, UtahSearch for more papers by this author First published: October 1996 https://doi.org/10.1111/j.1540-8183.1996.tb00643.xAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1 Laffel GL, Braunwald E. Thrombolytic therapy: A new strategy for the treatment of acute myocardial infarction. N Engl J Med 1984: 311: 710, 770. 2 Marder VJ, Sherry S. Thrombolytic therapy: Current status. N Engl J Med 1988; 318: 1512– 15204, 1585–15944. 3 Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm—paradoxic or predictable Circulation 1993; 88: 296– 306. 4 ISAM (Intravenous Streptokinase in Acute Myocardial Infarction) Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): Mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986; 314: 1465– 14714. 5 White HD, Norris RM, Brown MA, et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850– 855. 6 Guerci AD, Gerstenblith G, Brinker JA, et al. A randomized, placebo-controlled, double-blind trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N Engl J Med 1987; 317: 1613– 1618. 7 O'Rourke M, Baron D, Keogh A, et al. Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. Circulation 1988; 77: 1311– 1315. 8 Bassand J-P, Machecourt J, Cassagnes J, et al., For the APSIM Study Investigators. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Effects on infarct size and left ventricular function. JACC 1989; 13: 988– 9974. 9 Gruppo Italiano per lo Studio della Streptochinasi nell' Infarcto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; I: 397– 4014. 10 ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase. Oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; ii: 349– 3604. 11 Wilcox RG, Lippe GV, Olsson DB, et al. Trial of tissue plasminogen activator for mortality reduction for acute myocardial infarction: Anglo-Scandinavian study of early thrombolytic therapy (ASSET). Lancet 1988; ii: 525– 5304. 12 AIMS Trial Study Group. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study. Lancet 1990; 335: 427– 431. 13 Braunwald E. Myocardial reperfusion limitation of infarct size, reduction of left ventricular dysfunction, and improved survival. Should the paradigm be expanded Circulation 1989; 79: 441– 444. 14 Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992; 44: 293. 15 Fibrinolytic Therapy Trialists (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311– 322. 16 PRIMI Trial Study Group. Randomized double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; I: 863– 8684. 17 Neuhaus K-L, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded ad-ministration of alteplase: Results of the rt-PA—APSAC Patency Study (TAPS). JACC 1992; 19: 885. 18 The INJECT Study Group. A randomized, double blind comparison of reteplase, 10 + 10 MU double bolus administration, with streptokinase in patients with acute myocardial infarction (INJECT). Lancet 1995; 346: 329– 336. 19 Vanderschueren S, Barrios L, Kerdsinchai P, et al., For the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044– 20494. 20 Cannon CP, McCabe CH, Ghali M, et al., and the TIMI IOA Investigators. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1996 (In press). 21 ISIS-3 Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992; 339: 753. 22 The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71– 75. 23 Cannon CP, McCabe CH, Henry TD, et al, For the TIMI 5 Investigators. A pilot trial of recombinant desulfatohirudin compared to heparin in conjunction with tissue plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 Trial. JACC 1994; 23: 993– 10034. 24 The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956– 9614. 25 The GISSI-3 Investigators. Effects of lisinopril and transdermal glycery | trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: The Gruppo Italiano per lo Studio della Sopravvivenza nell'infarcto Miocardico (GISSI)-Study. Lancet 1994; 343: 1115– 1122. 26 ISIS-4 Collaborative Group. ISIS-4: A randomized factorial trial assessing, early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669– 685. 27 The European Myocardial Infarction Project Group (EMIP). Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med 1993; 329: 383. 28 Weaver WD, Cerqueira M, Hallstrom AP, et al, For the MITI Study Group. Prehospital-initiated vs hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention (MITI) Trial. JAMA 1993; 270: 1211– 12164. 29 Fuster V. Coronary thrombolysis-a perspective for the practicing physician. N Engl J Med 1993; 329: 723– 725. 30 Simoons ML, Arnold AE. Tailored thrombolytic therapy. A perspective. Circulation 1993; 88: 2556– 2564. 31 Anderson JL, Rothbard RL, Hackworthy RA, et al, For the APSAC Multicenter Investigators. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: Controlled comparison with intracoronary streptokinase. JACC 1988; 11: 1153– 11634. 32 Anderson JL, Sorensen SG, Moreno FL, et al, and the TEAM-2 Investigators. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction. Circulation 1991; 83: 126– 1404. 33 Anderson JL, Becker LC, Sorensen SG, et al, For the TEAM-3 Investigators. Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity, and 1 day patency. JACC 1992; 20: 753– 7664. 34 Braunwald E. The open-artery theory is alive and well again. N Engl J Med 1993; 329: 1650– 1652. 35 Simes RJ, Topol DJ, Holmes DR, et al, For the GUSTO-1 Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923– 19284. 36 Smith RAG, Dupe RJ, English PD, et al. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature 1981; 290: 505– 508. 37 Anderson JL, Boissel J-P, Chamberlain DA, (eds.): Symposium on anisoylated plasminogen streptokinase activator complex APSAC. Drugs 1987; 33(Suppl 3). 38 Anderson JL, Califf RA. Anisoylated plasminogen streptokinase activator complex (APSAC) in cardiovascular therapy. In: F Messerli, ed. Drugs for the Heart and Circulation. 2nd edition. Philadelphia . PA : WB Saunders. 1996. pp. 1553– 1566. 39 Marder VJ, Rothbard RL, Fitzpatrick PG, et al. Rapid lysis of coronary artery thrombi with anisoylated plasminogen-streptokinase activator complex: Treatment by bolus intravenous injection. Ann Intern Med 1986; 104: 304– 310. 40 Johnson ES, Cregeen RJ. Anisoylated plasminogen streptokinase activator complex in perspective: an interim report of efficacy and safety. Drugs 1987; 33(Suppl 13): 298– 3114. 41 Timmis AD, Griffin B, Crick J, et al. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: A placebo-controlled arteriographic coronary recanalization study. JACC 1987; 10: 205– 210. 42 Chesebro JH, Knatterud G, Roberts R, et al. Thrombolysis in myocardial infarction (TIMI) trial phase I: A comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation 1987; 76: 142– 154. 43 Bonnier HJRM, Visser RF, Klomps HC, et al, and the Dutch Invasive Reperfusion Study Group. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. Am J Cardiol 1988; 62: 25– 304. 44 Anderson JL, Karagounis LA, Califf RA. Metaanalysis of 5 reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996; 78: 1– 8. 45 Karagounis L, Ipsen S, Moreno F, et al, and the TEAM-2 Investigators. Effects of early thrombolytic therapy on enzymatic and electrocardiographic infarct size: results of a randomized, blinded study of anistreplase versus streptokinase in acute myocardial infarction. Am J Cardiol 1991; 68: 848– 8564. 46 Karagounis L, Sorensen SG, Menlove RL, et al, For the TEAM-2 Investigators. Does Thrombolysis In Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery, or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 study. JACC 1992; 19: 1– 104. 47 Anderson JL, Karagounis LA, Becker LC, et al, For the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction. Circulation 1993; 87: 1829– 18394. 48 Vogt A, Von Essen R, Tebbe U, et al. Impact of early perfusion status of the infarct-related artery on short term mortality after thrombolysis for acute myocardial infarction: Retrospective analysis of four German multicenter studies. JACC 1993; 21: 1391– 1395. 49 Simes RJ, Topol DJ, Holmes DR, et al. For the GUSTO-1 Investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Circulation 1995; 91: 1923– 1928. 50 Lincoff AM, Topol EJ, Califf RM, et al, For the TAMI Study Group. Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow “patency” outcome in the Thrombolysis and Angioplasty in Myocardial Infarction Trials). Am J Cardiol 1995; 75: 871– 8764. 51 Zahger D, Karagounis LA, Cercek B, et al, For the TEAM Investigators. Incomplete recanalization as an important determinant of thrombolysis in myocardial infarction (TIMI) grade 2 flow after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1995; 76: 749– 7524. 52 Moreno FM, Villanueva MA, Karagounis LA, et al, For the TEAM-2 Study Investigators. Reduction in QT interval dispersion by successful thrombolytic therapy in acute myocardial infarction. Circulation 1994; 90: 94– 1004. 53 Statters DJ, Malik M, Ward DE, et al. QT dispersion: Problems of methodology and clinical significance. J Cardiovasc Electrophysiol 1994; 5: 672– 685. 54 Mueller HS, Cohen LS, Braunwald E, et al, For the TIMI investigators. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Circulation 1992; 85: 1254– 12644. 55 Gomez MA, Karagounis LA, Allen A, et al, For the TEAM-2 Investigators. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Am J Cardiol 1993; 72: 373– 3784. 56 Neuhaus K-L, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded ad-ministration of alteplase: Results of the rt-PA—APSAC Patency Study (TAPS). JACC 1992; 19: 885. 57 Cannon CP, McCabe CH, Diver DJ, et al, and the TIMI 4 Investigators. Comparison of front-loaded tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 4 trial. JACC 1994; 24: 1602– 16104. 58 Karagounis LA, Anderson JL, Sorensen SG, et al, For the TEAM-3 Investigators. Relation of reperfusion success with anistreplase or alteplase in acute myocardial infarction to body weight. Am J Cardiol 1994; 73: 16– 224. 59 Karagounis LA, Moreno FM, Sorensen SG, et al, For the TEAM-3 Investigators. Multivariate determinants of QT dispersion in patients with acute myocardial infarction: Primary patency status of the infarct-related artery. Circulation 1994; 90: 1– 6624. 60 Cain ME, Anderson JL, Amsdorf MF, et al, For the American College of Cardiology. Signal-averaged electrocardiography expert consensus document. JACC 1996; 27: 238– 2494. 61 EI-Sherif N, Denes P, Katz R, et al, For the CAST/SAECG Substudy Investigators. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. JACC 1995; 25: 908– 9144. 62 Moreno FM, Karagounis L, Marshall H, et al. Thrombolysisrelated early patency reduces ECG late potential after myocardial infarction. Am Heart J 1992; 124: 557– 564. Volume9, Issue5October 1996Pages 361-372 ReferencesRelatedInformation
Referência(s)